Deutsche Bank Ag\ Axcella Health Inc. Transaction History

Deutsche Bank Ag\

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$3.08 - $5.13 $29,595 - $49,294	-9,609 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$4.55 - $6.72 $4,258 - $6,289	-936 Reduced 8.88%	9,609 $0
Q4 2020 Feb 16, 2021	BUY	$4.24 - $5.97 $9,794 - $13,790	2,310 Added 28.05%	10,545 $55,000
Q3 2020 Nov 12, 2020	BUY	$4.12 - $5.91 $12,907 - $18,516	3,133 Added 61.41%	8,235 $38,000
Q2 2020 Aug 13, 2020	BUY	$2.94 - $7.7 $7,776 - $20,366	2,645 Added 107.65%	5,102 $28,000
Q1 2020 May 14, 2020	SELL	$2.25 - $5.24 $351 - $817	-156 Reduced 5.97%	2,457 $8,000
Q4 2019 Feb 14, 2020	BUY	$3.08 - $5.9 $6,717 - $12,867	2,181 Added 504.86%	2,613 $10,000
Q3 2019 Nov 14, 2019	SELL	$5.25 - $9.26 $4,179 - $7,370	-796 Reduced 64.82%	432 $2,000
Q2 2019 Aug 14, 2019	BUY	$8.51 - $14.95 $10,450 - $18,358	1,228 New	1,228 $11,000

61.6K

Ticker AXLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,500,896
Description
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrenc...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.